AstraZeneca MYSTIC Read-Out Delay Further Boost To Merck
Executive Summary
Overall survival data are now not due until the second half of the year but however they turn out competitor Merck & Co is still expected to dominate the late-stage NSCLC market with Keytruda.
You may also be interested in...
ARCTIC Chill Descends On AstraZeneca's Imfinzi/Treme Combo In NSCLC
Failure of the ARCTIC study was considered likely and will do little to dent Imfinzi's overall sales prospects but cools sentiment on the CTLA4 inhibitor tremelimumab.
Merck's Keytruda Set For Expanded Use As Lung Cancer Monotherapy
Data showing overall survival benefit for Keytruda in patients with at least 1% PD-L1 expression ups the ante for competitors Bristol and Roche, which will be presenting data for combinations in lung cancer at the American Association of Clinical Research meeting in April.
AstraZeneca's Imfinzi Scores First Early Lung Cancer Approval
Unlike other indications PD-1/L1 inhibitors are shooting for, Stage III non-small cell lung cancer is an untapped market and AstraZeneca will have the space to itself for a while.